CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $3.54B, above the global median of $1.2B
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.54BUSDvs all stocks (USD)
Revenue (TTM)
234.13MUSDvs all stocks (USD)
Profit Margin
-74.75%vs Biotechnology peers
Beta
-0.0760xvs all stocks
52-Week Change
34.94%vs all stocks
Market Capitalization
3.54BUSDvs all stocks (USD)
Enterprise Value
2.74BUSDvs all stocks (USD)
Forward P/E
-8.95xvs Biotechnology peers
Price to Sales (TTM)
15.12xvs Biotechnology peers
Price to Book (MRQ)
2.95xvs Biotechnology peers
Enterprise to Revenue
11.71xvs Biotechnology peers
Enterprise to EBITDA
-12.79xvs Biotechnology peers
Profit Margin
-74.75%vs Biotechnology peers
Operating Margin
-1380.73%vs Biotechnology peers
Return on Assets (TTM)
-11.54%vs Biotechnology peers
Return on Equity (TTM)
-16.22%vs Biotechnology peers
Revenue (TTM)
234.13MUSDvs all stocks (USD)
Revenue per Share (TTM)
2.62USDUpdated Sep 27, 2026Quarterly Revenue Growth
35.02%vs Biotechnology peers
Gross Profit (TTM)
-139.88MUSDvs all stocks (USD)
EBITDA (TTM)
-214.20MUSDvs all stocks (USD)
Net Income (TTM)
-175.02MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-111.66MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-70.85MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
218.71MUSDFY2025 · Dec 31, 2025Operating Income
-159.31MUSDvs all stocks (USD)
Pre-tax Income
-113.70MUSDFY2025 · Dec 31, 2025Net Income
-113.70MUSDFY2025 · Dec 31, 2025EBIT
-159.31MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-154.72MUSDFY2025 · Dec 31, 2025Research & Development
314.70MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
63.32MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
45.62MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-113.70MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-63.71MUSDFY2025 · Dec 31, 2025Free Cash Flow
-66.08MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
113.84MUSDFY2025 · Dec 31, 2025Interest Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-113.70MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
4.59MUSDFY2025 · Dec 31, 2025Stock-based Compensation
46.12MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
0.00USDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
2.70MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-3.42MUSDFY2025 · Dec 31, 2025Capital Expenditures
-2.37MUSDFY2025 · Dec 31, 2025Purchase of Investments
-607.89MUSDFY2025 · Dec 31, 2025Sale of Investments
680.23MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
69.98MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
24.86MUSDFY2025 · Dec 31, 2025Shares Outstanding
96.38MSharesUpdated Sep 27, 2026Float Shares
90.63MSharesUpdated Sep 27, 2026Shares Short
9.93MSharesUpdated Sep 27, 2026Short Ratio
13.85daysvs all stocks
Short % of Shares Outstanding
11.96%vs all stocks
% Held by Insiders
2.19%vs all stocks
% Held by Institutions
108.15%vs all stocks
Total Cash (MRQ)
828.96MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
8.59USDUpdated Sep 27, 2026Total Debt (MRQ)
29.31MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0244xvs Biotechnology peers
Current Ratio (MRQ)
10.45xvs Biotechnology peers
Book Value per Share (MRQ)
12.44USDUpdated Sep 27, 2026Total Assets
1.11BUSDvs all stocks (USD)
Total Current Assets
666.73MUSDFY2025 · Dec 31, 2025Total Liabilities
86.39MUSDFY2025 · Dec 31, 2025Total Non-current Assets
442.60MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
27.57MUSDFY2025 · Dec 31, 2025Total Current Liabilities
58.81MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
112.83MUSDFY2025 · Dec 31, 2025Other Short-term Investments
526.56MUSDFY2025 · Dec 31, 2025Accounts Payable
17.58MUSDFY2025 · Dec 31, 2025Short-term Debt
339.00KUSDFY2025 · Dec 31, 2025Long-term Debt
27.57MUSDFY2025 · Dec 31, 2025Common Stock (Book)
9.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-736.54MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.02BUSDvs all stocks (USD)
52-Week Low
26.05USDUpdated Sep 27, 202652-Week High
42.68USDUpdated Sep 27, 202652-Week Change
34.94%vs all stocks
Beta
-0.0760xvs all stocks
50-Day MA
37.78USDUpdated Sep 27, 2026200-Day MA
33.97USDUpdated Sep 27, 2026Avg 10-Day Volume
1.04MSharesUpdated Sep 27, 2026Avg 30-Day Volume
823.46KSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-1.92USDUpdated Sep 27, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $3.54B, above the global median of $1.2BNotable
Market cap (USD): 3,540,199,167Global Median: 1,201,862,193
Companies that share the same coordination system — how they create, deliver, or capture value.
Tarsus Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Pegbio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Xenon Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hualan Biological Engineering Inc.
Tier 1ProductionApproval-Gated PipelineRule
Acadia Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Organon & Co.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Livzon Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ambu A/S
Tier 1ProductionApproval-Gated PipelineRuleFlow
Laboratorios Farmacéuticos Rovi SA
Tier 1ProductionApproval-Gated PipelineRuleFlow
Irhythm Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking